Cargando…

Factors contributing to delays in initiation of front-line cervical cancer therapy: disparities in a diverse south Florida population

OBJECTIVE: Delay in initiating cervical cancer treatment may impact outcomes. In a cohort of patients initially treated by surgery, chemoradiation, chemotherapy, or in a clinical trial, we aim to define factors contributing to prolonged time to treatment initiation. METHODS: Data from patients initi...

Descripción completa

Detalles Bibliográficos
Autores principales: Roy, Molly, Finch, Lindsey, Kwon, Deukwoo, Jordan, Scott E, Yadegarynia, Sina, Wolfson, Aaron Howard, Slomovitz, Brian, Portelance, Lorraine, Huang, Marilyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664089/
https://www.ncbi.nlm.nih.gov/pubmed/36198435
http://dx.doi.org/10.1136/ijgc-2022-003475
_version_ 1784831027544326144
author Roy, Molly
Finch, Lindsey
Kwon, Deukwoo
Jordan, Scott E
Yadegarynia, Sina
Wolfson, Aaron Howard
Slomovitz, Brian
Portelance, Lorraine
Huang, Marilyn
author_facet Roy, Molly
Finch, Lindsey
Kwon, Deukwoo
Jordan, Scott E
Yadegarynia, Sina
Wolfson, Aaron Howard
Slomovitz, Brian
Portelance, Lorraine
Huang, Marilyn
author_sort Roy, Molly
collection PubMed
description OBJECTIVE: Delay in initiating cervical cancer treatment may impact outcomes. In a cohort of patients initially treated by surgery, chemoradiation, chemotherapy, or in a clinical trial, we aim to define factors contributing to prolonged time to treatment initiation. METHODS: Data from patients initiating treatment for cervical cancer at a single institution was abstracted. Time to treatment initiation was defined as the interval from the date of cancer diagnosis to the date of treatment initiation. Poisson regression model was used for analysis. RESULTS: Of 274 patients studied, the median time to treatment initiation was 60 days (range 0–551). The median times to initiate surgery (54 days, range 3–96) and chemoradiation (58 days, range 4–187) were not significantly different (relative risk (RR) 1.01, 95% CI 0.98 to 1.04, p=0.54). The shortest median initiation time was for chemotherapy (47 days; RR 1.13, 95% CI 1.08 to 1.19, p<0.0001) and the longest was for clinical trial (62 days; RR 1.18, 95% CI 1.12 to 1.24, p<0.0001). Charity care (RR 1.09, 95% CI 1.05 to 1.14, p<0.0001), Medicare or Medicaid (RR 1.10, 95% CI 1.06 to 1.14, p<0.0001), and self-pay (RR 1.38, 95% CI 1.32 to 1.45, p<0.0001) delayed treatment initiation more than private insurance. Hispanic White women (RR 0.69, 95% CI 0.66 to 0.73, p<0.0001) had a shorter treatment initiation time compared with non-Hispanic White patients, while Afro-Caribbean/Afro-Latina women (RR 0.86, 95% CI 0.81 to 0.90, p<0.0001) and African-American patients (RR 1.13, 95% CI 1.07 to 1.19, p<0.0001) had longer initiation times. Spanish speaking patients did not have a prolonged treatment initiation (RR 0.68, 95% CI 0.66 to 0.71, p<0.0001), though Haitian-Creole speaking patients did (RR 1.07, 95% CI 1.01 to 1.13, p<0.002). Diagnosis at an outside institution delayed treatment initiation time (RR 1.24, 95% CI 1.18 to 1.30, p<0.0001) compared with diagnosis at the cancer center. CONCLUSION: Factors associated with prolonged time to treatment initiation include treatment modality, insurance status, language spoken, and institution of diagnosis. By closely examining each of these factors, barriers to treatment can be identified and modified to shorten treatment initiation time.
format Online
Article
Text
id pubmed-9664089
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-96640892022-11-15 Factors contributing to delays in initiation of front-line cervical cancer therapy: disparities in a diverse south Florida population Roy, Molly Finch, Lindsey Kwon, Deukwoo Jordan, Scott E Yadegarynia, Sina Wolfson, Aaron Howard Slomovitz, Brian Portelance, Lorraine Huang, Marilyn Int J Gynecol Cancer Original Research OBJECTIVE: Delay in initiating cervical cancer treatment may impact outcomes. In a cohort of patients initially treated by surgery, chemoradiation, chemotherapy, or in a clinical trial, we aim to define factors contributing to prolonged time to treatment initiation. METHODS: Data from patients initiating treatment for cervical cancer at a single institution was abstracted. Time to treatment initiation was defined as the interval from the date of cancer diagnosis to the date of treatment initiation. Poisson regression model was used for analysis. RESULTS: Of 274 patients studied, the median time to treatment initiation was 60 days (range 0–551). The median times to initiate surgery (54 days, range 3–96) and chemoradiation (58 days, range 4–187) were not significantly different (relative risk (RR) 1.01, 95% CI 0.98 to 1.04, p=0.54). The shortest median initiation time was for chemotherapy (47 days; RR 1.13, 95% CI 1.08 to 1.19, p<0.0001) and the longest was for clinical trial (62 days; RR 1.18, 95% CI 1.12 to 1.24, p<0.0001). Charity care (RR 1.09, 95% CI 1.05 to 1.14, p<0.0001), Medicare or Medicaid (RR 1.10, 95% CI 1.06 to 1.14, p<0.0001), and self-pay (RR 1.38, 95% CI 1.32 to 1.45, p<0.0001) delayed treatment initiation more than private insurance. Hispanic White women (RR 0.69, 95% CI 0.66 to 0.73, p<0.0001) had a shorter treatment initiation time compared with non-Hispanic White patients, while Afro-Caribbean/Afro-Latina women (RR 0.86, 95% CI 0.81 to 0.90, p<0.0001) and African-American patients (RR 1.13, 95% CI 1.07 to 1.19, p<0.0001) had longer initiation times. Spanish speaking patients did not have a prolonged treatment initiation (RR 0.68, 95% CI 0.66 to 0.71, p<0.0001), though Haitian-Creole speaking patients did (RR 1.07, 95% CI 1.01 to 1.13, p<0.002). Diagnosis at an outside institution delayed treatment initiation time (RR 1.24, 95% CI 1.18 to 1.30, p<0.0001) compared with diagnosis at the cancer center. CONCLUSION: Factors associated with prolonged time to treatment initiation include treatment modality, insurance status, language spoken, and institution of diagnosis. By closely examining each of these factors, barriers to treatment can be identified and modified to shorten treatment initiation time. BMJ Publishing Group 2022-11 2022-10-05 /pmc/articles/PMC9664089/ /pubmed/36198435 http://dx.doi.org/10.1136/ijgc-2022-003475 Text en © IGCS and ESGO 2022. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Roy, Molly
Finch, Lindsey
Kwon, Deukwoo
Jordan, Scott E
Yadegarynia, Sina
Wolfson, Aaron Howard
Slomovitz, Brian
Portelance, Lorraine
Huang, Marilyn
Factors contributing to delays in initiation of front-line cervical cancer therapy: disparities in a diverse south Florida population
title Factors contributing to delays in initiation of front-line cervical cancer therapy: disparities in a diverse south Florida population
title_full Factors contributing to delays in initiation of front-line cervical cancer therapy: disparities in a diverse south Florida population
title_fullStr Factors contributing to delays in initiation of front-line cervical cancer therapy: disparities in a diverse south Florida population
title_full_unstemmed Factors contributing to delays in initiation of front-line cervical cancer therapy: disparities in a diverse south Florida population
title_short Factors contributing to delays in initiation of front-line cervical cancer therapy: disparities in a diverse south Florida population
title_sort factors contributing to delays in initiation of front-line cervical cancer therapy: disparities in a diverse south florida population
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664089/
https://www.ncbi.nlm.nih.gov/pubmed/36198435
http://dx.doi.org/10.1136/ijgc-2022-003475
work_keys_str_mv AT roymolly factorscontributingtodelaysininitiationoffrontlinecervicalcancertherapydisparitiesinadiversesouthfloridapopulation
AT finchlindsey factorscontributingtodelaysininitiationoffrontlinecervicalcancertherapydisparitiesinadiversesouthfloridapopulation
AT kwondeukwoo factorscontributingtodelaysininitiationoffrontlinecervicalcancertherapydisparitiesinadiversesouthfloridapopulation
AT jordanscotte factorscontributingtodelaysininitiationoffrontlinecervicalcancertherapydisparitiesinadiversesouthfloridapopulation
AT yadegaryniasina factorscontributingtodelaysininitiationoffrontlinecervicalcancertherapydisparitiesinadiversesouthfloridapopulation
AT wolfsonaaronhoward factorscontributingtodelaysininitiationoffrontlinecervicalcancertherapydisparitiesinadiversesouthfloridapopulation
AT slomovitzbrian factorscontributingtodelaysininitiationoffrontlinecervicalcancertherapydisparitiesinadiversesouthfloridapopulation
AT portelancelorraine factorscontributingtodelaysininitiationoffrontlinecervicalcancertherapydisparitiesinadiversesouthfloridapopulation
AT huangmarilyn factorscontributingtodelaysininitiationoffrontlinecervicalcancertherapydisparitiesinadiversesouthfloridapopulation